Cytek Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and its Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .FREMONT, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the upcoming 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA.
加利福尼亚州弗里蒙特，2025年1月2日（全球新闻网）-- Cytek生物科学公司（纳斯达克：CTKB），一家领先的电芯分析解决方案公司，今天宣布公司将参加即将在加利福尼亚州旧金山举行的第43届年度摩根大通医疗大会。
Cytek management is scheduled to present on Thursday, January 16th at 8:15 a.m. Pacific Time / 11:15 a.m. Eastern Time. Interested parties may access a live and archived webcast of the presentation on the "Investors" section of the company website at: investors.cytekbio.com.
赛泰克管理层计划于1月16日（星期四）太平洋时间上午8:15 / 东部时间上午11:15进行演讲。相关方可以通过公司网站的“投资者”部分访问该演讲的现场直播和归档网络广播：investors.cytekbio.com。
About Cytek Biosciences, Inc.
关于Cytek Biosciences, Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading cell analysis solutions company advancing the next generation of cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Cytek's novel approach harnesses the power of information within the entire spectrum of a fluorescent signal to achieve a higher level of multiplexing with precision and sensitivity. Cytek's platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and its Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Cytek is headquartered in Fremont, California with offices and distribution channels across the globe. More information about the company and its products is available at .
赛泰克生物科学公司（纳斯达克：CTKB）是一家领先的电芯分析解决方案公司，通过提供高分辨率、高含量和高灵敏度的电芯分析，推动下一代电芯分析工具的发展，利用其专利的全光谱分析（FSP）科技。赛泰克独特的方法利用荧光信号整个光谱中的信息，实现精确和敏感的更高水平的多重分析。赛泰克的平台包括其核心FSP仪器，赛泰克Aurora和Northern Lights系统以及其赛泰克Aurora CS电芯分选机；赛泰克Orion试剂混合物制备系统；增强小颗粒（ESP）检测技术；以及在Amnis和Guava品牌下的流式细胞仪和成像产品；还提供试剂、软件和服务，为客户提供全面和综合的解决方案。赛泰克总部位于加利福尼亚州弗里蒙特，业务覆盖全球各地。有关公司及其产品的更多信息，请访问。
Cytek's products are for research use only and not for use in diagnostic procedures (other than Cytek's Northern Lights-CLC system and certain reagents, which are available for clinical use in China and the European Union).
Cytek的产品仅供研究使用，不得用于诊断程序（除Cytek的Northern Lights-CLC系统和某些试剂外，这些试剂在中国和欧盟可用于临床）。
Cytek, Full Spectrum Profiling, FSP, Cytek Aurora, Northern Lights, Cytek Orion, Enhanced Small Particle, ESP, Amnis and Guava are trademarks of Cytek Biosciences, Inc.
Cytek、全光谱分析、FSP、Cytek Aurora、Northern Lights、Cytek Orion、增强型小颗粒、ESP、Amnis和Guava是Cytek Biosciences, Inc.的商标。
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Cytek uses its website (), LinkedIn page and X (formerly Twitter) account as channels of distribution of information about its company, products, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Cytek may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Cytek's website, LinkedIn page, and X account in addition to following its SEC filings, news releases, public conference calls and webcasts.
除了向证券交易委员会（SEC）提交的文件、新闻稿、公开电话会议和网络广播外，Cytek还通过其网站（）、LinkedIn页面和X（前身为Twitter）账户作为传播公司、产品、计划财务和其他公告、即将举行的投资者和行业会议的出席情况以及其他事项的信息渠道。这些信息可能被视为重要信息，Cytek可能会利用这些渠道履行其在《FD规定》下的披露义务。因此，投资者应除了关注Cytek的SEC文件、新闻稿、公开电话会议和网络广播外，还应监控Cytek的网站、LinkedIn页面和X账户。
Media Contact:
Stephanie Olsen
Lages & Associates
(949) 453-8080
stephanie@lages.com
媒体联系人：
斯蒂芬妮·奥尔森
拉格斯与合伙人
(949) 453-8080
stephanie@lages.com
Investor Contact:
Paul Goodson
Head of Investor Relations
Cytek Biosciences
pgoodson@cytekbio.com
投资者联系人：
保罗·古德森
投资者关系负责人
Cytek生物科学
pgoodson@cytekbio.com
Source: Cytek Biosciences, Inc.
来源: Cytek Biosciences, Inc.
